Sponsor Directory

Novartis Pharmaceuticals clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1758

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Sickle Cell Disease
Interventions: Crizanlizumab, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 13 more

Conditions: Lupus Nephritis
Interventions: ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 25
States / cities: Birmingham, Alabama • La Palma, California • Orange, California + 20 more

Conditions: Metastatic Neuroendocrine Prostate Cancer
Interventions: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Interventions: ianalumab, thrombopoietin receptor agonist (TPO-RA); Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Fayetteville, Arkansas • Torrance, California • New Haven, Connecticut + 15 more

Conditions: Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
Interventions: Drug: Atrasentan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more

Conditions: Hypertension
Interventions: E3 Multidisciplinary Team, E3 Self-Guided Hypertension Education Program; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lupus Nephritis
Interventions: Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • San Bernardino, California • Sylmar, California + 13 more

Conditions: Prostate Cancer
Interventions: AAA817, ARPI, Standard of Care; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 42
States / cities: Homewood, Alabama • Tucson, Arizona • Orange, California + 37 more

Conditions: Chagas Disease
Interventions: LXE408, Placebo, Benznidazole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Sylmar, California • Gainesville, Florida • Boston, Massachusetts + 1 more

Conditions: Sjogrens Syndrome
Interventions: Ianalumab (VAY736), Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 32
States / cities: Fullerton, California • La Palma, California • Van Nuys, California + 27 more

Conditions: Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Interventions: NIO752, Placebo; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 41 Years to 81 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Francisco, California • Englewood, Colorado + 6 more

Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Interventions: Iptacopan, Placebo, Rituximab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Mesa, Arizona • Rochester, Minnesota

About this Novartis Pharmaceuticals sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Novartis Pharmaceuticals is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Novartis Pharmaceuticals trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Novartis Pharmaceuticals clinical trials

Filter and sort this sponsor

Live official records

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

E3 Hypertension - A Team-based, Multidisciplinary Model in Addressing Barriers to Hypertension Control

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

Iptacopan in Patients With ANCA Associated Vasculitis

About this Novartis Pharmaceuticals sponsor directory page